CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Lumos Diagnostics Holdings Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Lumos Diagnostics Holdings Ltd
100 Albert Rd, Level 4
Phone: +61 390871598p:+61 390871598 SOUTH MELBOURNE, VIC  3205  Australia Ticker: LDXLDX
Business Summary
Lumos Diagnostics Holdings Ltd is an Australia-based company, which specializes in point-of-care (POC) diagnostic test technology to help healthcare professionals diagnose and manage medical conditions. The Company offers customized assay development and manufacturing services for POC tests and digital reader platforms. It also directly develops, manufactures, and commercializes, Lumos-branded POC tests that target infectious and inflammatory diseases. The Company’s products include FEBRIDX, COVIDX, and ViraDx. FebriDx is a point-of-care test which can be used to detect and aid in differentiating bacterial from viral acute respiratory infections. ViraDx is a point-of-care, three-in-one COVID-19/Flu A/Flu B rapid antigen test. Its services include assay development, reader development, cloud and data, and manufacturing. It manages the full development program for point-of-care (POC) assays, from sourcing and/or generation of reagents, right through to verification and validation.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20236/30/2023Yes----

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
2834 Pharmaceutical preparations
3845 Electromedical and electrotherapeutic apparatus

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board SamuelLanyon 6/6/2022 1/1/2019
Chief Executive Officer, Managing Director, Director DougWard 7/13/2023 6/15/2022
Non-Executive Deputy Chairman of the Board LawrenceMehren 53 12/16/2020 12/16/2020
10 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 481,300,042 (As of 12/31/2023)
Shareholders: 1,129
Stock Exchange: ASX


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 20, 2024